S

T

STANBURY , T.

Last name: STANBURY

First name: T.

September 8, 2017 (v1)

Conference paper

Metadata-only

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Bennouna, J. Hiret, S. Borg, C.

International audience

Uploaded on: March 26, 2023
October 7, 2016 (v1)

Conference paper

Metadata-only

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

Bidard, François-Clément Ychou, M. Madic, J.

Background: We prospectively detected circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) levels in patients (pts) included in the PRODIGE14-ACCORD21-METHEP2 randomized phase II trial.Methods: The trial enrolled colorectal cancer pts with potentially resectable liver metastases & no prior treatment; the primary endpoint was the rate...

Uploaded on: February 28, 2023